Key facts
- This page summarizes Sam Samad's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 May 2022, 18:10.
Sam Samad - 11 May 2022 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)
- Reporting relationship
- Director
- Issuer ticker
- IDXX
- Reported as of
- 11 May 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 May 2022, 18:10:33 UTC
- Prior SEC filing
- 03 Mar 2022
- Next SEC filing
- 26 Jul 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Lily J. Lu, Attorney-in-Fact for Sam Samad
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Sam Samad filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 13 May 2022.
Change
- Previous filing in this sequence was filed on 03 Mar 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IDXX
transaction
Derivative
Deferred Stock Unit
Award
- Transaction value
- Shares
- +344
- Change %
- Price
- Shares after
- 344
- Date
- 11 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 344
- Exercise price
- Footnotes
- F1, F3
IDXX
transaction
Derivative
Non-Qualified Stock Option (right-to-buy)
Award
- Transaction value
- Shares
- +945
- Change %
- Price
- Shares after
- 945
- Date
- 11 May 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 945
- Exercise price
- $333.90
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.
Footnote F2
Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event is earlier.
Footnote F3
Not applicable.